A PHASE 1, RANDOMIZED, OPEN-LABEL, TWO-WAY CROSSOVER STUDY TO EVALUATE THE STEADY-STATE EFFECT OF DIMEBON (PF 01913539) ON THE SINGLE-DOSE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN IN HEALTHY SUBJECTS: